Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

A point mutation in the dynein heavy chain gene leads to striatal atrophy and compromises neurite outgrowth of striatal neurons

In English

Författare

  • Kerstin E. Braunstein
  • Judith Eschbach
  • Krisztina Rona-Voeroes
  • Rana Soylu
  • Elli Mikrouli
  • Yves Larmet
  • Frederique Rene
  • Jose-Luis Gonzalez De Aguilar
  • Jean-Philippe Loeffler
  • Hans-Peter Mueller
  • Selina Bucher
  • Thomas Kaulisch
  • Heiko G. Niessen
  • Julia Tillmanns
  • Kristina Fischer
  • Birgit Schwalenstoecker
  • Jan Kassubek
  • Bernd Pichler
  • Detlef Stiller
  • Åsa Petersén
  • Albert C. Ludolph
  • Luc Dupuis
Visa allt

Summary, in English

The molecular motor dynein and its associated regulatory subunit dynactin have been implicated in several neurodegenerative conditions of the basal ganglia, such as Huntington's disease (HD) and Perry syndrome, an atypical Parkinson-like disease. This pathogenic role has been largely postulated from the existence of mutations in the dynactin subunit p150(Glued). However, dynactin is also able to act independently of dynein, and there is currently no direct evidence linking dynein to basal ganglia degeneration. To provide such evidence, we used here a mouse strain carrying a point mutation in the dynein heavy chain gene that impairs retrograde axonal transport. These mice exhibited motor and behavioural abnormalities including hindlimb clasping, early muscle weakness, incoordination and hyperactivity. In vivo brain imaging using magnetic resonance imaging showed striatal atrophy and lateral ventricle enlargement. In the striatum, altered dopamine signalling, decreased dopamine D1 and D2 receptor binding in positron emission tomography SCAN and prominent astrocytosis were observed, although there was no neuronal loss either in the striatum or substantia nigra. In vitro, dynein mutant striatal neurons displayed strongly impaired neuritic morphology. Altogether, these findings provide a direct genetic evidence for the requirement of dynein for the morphology and function of striatal neurons. Our study supports a role for dynein dysfunction in the pathogenesis of neurodegenerative disorders of the basal ganglia, such as Perry syndrome and HD.

Publiceringsår

2010

Språk

Engelska

Sidor

4385-4398

Publikation/Tidskrift/Serie

Human Molecular Genetics

Volym

19

Issue

22

Dokumenttyp

Artikel i tidskrift

Förlag

Oxford University Press

Ämne

  • Medical Genetics

Status

Published

Forskningsgrupp

  • Translational Neuroendocrinology

ISBN/ISSN/Övrigt

  • ISSN: 0964-6906